U.K. begins large trial of new COVID-19 treatment inhaled into the lungs


Britain on Tuesday began a large-scale trial of a new COVID-19 treatment in which patients inhale aerosolized interferon beta proteins into the lungs with a nebulizer. The treatment, developed at Southampton University Hospital and produced by biotech firm Synairgen, cut the odds of COVID-19 patients developing severe symptoms by nearly 80 percent, according to a small, phase 2 trial of 100 patients. The new phase 3 study involves more than 600 subjects in 20 countries, half of whom will get the treatment and half a placebo inhalant.
The body produces interferon beta to fight off viral infections, but the new coronavirus appears to suppress production of the proteins as part of its mechanism to evade patients' immune responses, BBC News reports. Synairgen hopes a direct shot of aerosolized interferon beta straight to the lungs will provoke a strong anti-viral response. The early results are promising, but experts warn that promising treatments don't always pan out.
"We've had other drugs in similar circumstances, we've had hydroxychloroquine, for example," Dr. Lamis Latif tells BBC News. "But again, when that reached further trials, it wasn't as promising as it initially made up to be.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Exurbs: America's biggest housing trend you haven't heard of
Under the Radar Northeastern exurbs were the nation's biggest housing markets in 2024
-
How to enjoy a coolcation in Sweden
The Week Recommends You won't break a sweat on Lake Asnen or underground at the Adventure Mine
-
Sudoku medium: May 8, 2025
The Week's daily medium sudoku puzzle
-
Warren Buffet announces surprise retirement
speed read At the annual meeting of Berkshire Hathaway, the billionaire investor named Vice Chairman Greg Abel his replacement
-
Trump calls Amazon's Bezos over tariff display
Speed Read The president was not happy with reports that Amazon would list the added cost from tariffs alongside product prices
-
Markets notch worst quarter in years as new tariffs loom
Speed Read The S&P 500 is on track for its worst month since 2022 as investors brace for Trump's tariffs
-
Tesla Cybertrucks recalled over dislodging panels
Speed Read Almost every Cybertruck in the US has been recalled over a stainless steel panel that could fall off
-
Crafting emporium Joann is going out of business
Speed Read The 82-year-old fabric and crafts store will be closing all 800 of its stores
-
Trump's China tariffs start after Canada, Mexico pauses
Speed Read The president paused his tariffs on America's closest neighbors after speaking to their leaders, but his import tax on Chinese goods has taken effect
-
Chinese AI chatbot's rise slams US tech stocks
Speed Read The sudden popularity of a new AI chatbot from Chinese startup DeepSeek has sent U.S. tech stocks tumbling
-
US port strike averted with tentative labor deal
Speed Read The strike could have shut down major ports from Texas to Maine